You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
Development of a Bio-tissue Oxygenation Nanophosphor Enabled Sensing (BONES) system for Quantifying Hypoxia in Bone MarrowSBC: SIGRAY, INC. Topic: 400
Project Summary/Abstract Low oxygen (hypoxic) environments are known to be important for maintaining the small number of adult stem cells in the human body, such as in bone marrow. These conditions are also believed to enable dormant cancer cells to survive and metastasize years or decades after the original tumor has been destroyed and the reason why bone marrow is one of the most common sites of ...STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
Translating an In-Person Brief, Bystander Bullying Intervention (STAC) to a Technology-Based- Phase IISBC: KLEIN BUENDEL, INC. Topic: 102
While studies support the efficacy of comprehensive, school-wide interventions in reducing bullying, these types of programs can require significant time and financial resources for implementation, resulting in barriers to providing school-based bullying prevention, especially in low-income and rural communities. Additionally, although training bystanders to act as “defenders” on behalf of tar ...STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
Developing generalized engineering tools to create enhanced phage therapy for the clinic and commercializationSBC: FELIX BIOTECHNOLOGY INC Topic: NIAID
ABSTRACT Antibiotic-resistant infections are a major public health threat in the U.S. and globally, with Pseudomonas aeruginosa (Pa) being one of the top pathogens of concern. Phage therapy is a promising approach to treat these infections, with benefits of species-targeted activity that spares the host microbiome, an ability to penetrate biofilms and kill metabolically-inactive persister cells, a ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
Developing Vertebrate-Specific Replication-Defective Dengue Virus as Novel Single-CycleDengue Vaccine CandidateSBC: Tengen Biomedical Co Topic: NIAID
Developing Vertebrate-Specific Replication-Defective Dengue Virus asa Novel Single-Cycle Dengue Vaccine Candidate Abstract With an estimated minimum of 390 million dengue virus (DENV) infections per year, the DENV epidemic was listed as one of the worldandapos;s top 10 public health threats by WHO in 2019. At present, there is no specific treatment. A universal vaccine is urgently needed. DENV vac ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: InnoTech Precision Medicine, Inc Topic: NIDCR
Original Abstract A multimodal platform for Oral screening of COVID-19 The development of a rapid and reliable sensor system from readily available oral specimens is crucial for the screening and management of SARS-CoV-2 infection. Other than tests that require laboratory-scale instrumentation, the development of rapid tests can play a timely role in the management of an outbreak. Current rapid te ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: ACADEMIC WEB PAGES, INC Topic: 104
Project Summary/Abstract (30 lines) In the United States, 15 million children and adolescents need psychological services; yet only one-third receive psychological services of any kind. Even fewer receive care that is consistent with evidence-based guidelines for best practices. This gap has widened dramatically with the negative effects of the COVID-19 pandemic on the mental health of children, c ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
AI-Based Identification of Rapid Glaucoma Progression to Guide Clinical Management and Accelerate Clinical TrialsSBC: AISIGHT HEALTH INC Topic: 100
Project Summary Glaucoma is the leading cause of irreversible blindness worldwide and is expected to affect more than 110 million people worldwide within the next two decades. It is a degenerative disease that has a large impact both in terms of patient quality of life and in costs to the healthcare system. A critical need in glaucoma clinical management and research is the ability to accurately i ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic NeuritisSBC: TRIANGLE THERAPEUTICS INC. Topic: 100
PROJECT SUMMARY Optic neuritis (ON) is an acute autoimmune disease caused by immune attack on the myelin that protects the optic nerve leading to vision loss. Steroid treatments accelerate recovery of visual acuity in some patients but have no effect on other visual functions such as contrast sensitivity that are important for activities of daily life. Even with steroid treatments, 13,000 ON patie ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
EXODUS-enabled High-throughput Multi-omics Profiling of Extracellular Vesicles for Diagnosis of Preclinical Alzheimer's DiseaseSBC: WELLSIM BIOMEDICAL TECHNOLOGIES INC Topic: NIA
PROJECT SUMMARY / ABSTRACT Alzheimerandapos;s disease (AD) is the most widespread neurodegenerative disorder and has caused a major global health concern with the aging population. Early diagnosis of AD before irreversible brain damage or mental decline is critical for timely intervention, symptomatic treatment, and improved patient function. Accumulating studies indicate that neuron-derived extra ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: NEUIMMUNE BIOLOGICS, INC. Topic: NHLBI
ABSTRACTAlpha-1 antitrypsin (A1AT) is well-established as a biotherapeutic used for the treatment of alpha-1 antitrypsin deficiency, and shows promise for treating a variety of other diseases. However, A1AT augmentation therapy carries unnecessary risk since it relies upon the weekly transfusion of plasma-derived product, which presents supply chain and contaminant risks. This could be remedied wi ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health